Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of May 21, 2026, MYGN trades at $3.79 with a market cap of $344.74M and a P/E ratio of -0.86. MYGN moved +6.76% today. Year to date, MYGN is -37.95%; over the trailing twelve months it is -14.38%. Its 52-week range spans $3.53 to $27.55. Analyst consensus is neutral with an average price target of $7.20. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Myriad Genetics Inc (MYGN) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. MYGN moved +6.76% today. Analyst consensus is neutral.
| Metric | Value |
|---|---|
| Price | $3.79 |
| Market Cap | $344.74M |
| P/E Ratio | -0.86 |
| EPS | $-4.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.55 |
| 52-Week Low | $3.53 |
| Volume | 1.71M |
| Avg Volume | 0 |
| Revenue (TTM) | $829.00M |
| Net Income | $-399.90M |
| Gross Margin | 69.96% |
7 analysts cover MYGN: 0 strong buy, 2 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.20.